Montgomery Community Media

Vaccine development company Novavax, headquartered in Gaithersburg, announced Monday that it expanded Phase 3 clinical trials for its COVID-19 vaccine candidate to include adolescents. The trials will include up to 3,000 youths ages 12-17 at up to 75 sites in the U.S., the company said in a press release. “Through the expansion of our PREVENT-19 […]

Altimmune, Inc. announced Wednesday that it was approved by the FDA to begin Phase 1 clinical trials for AdCOVID, its single-dose nasal spray COVID-19 vaccine candidate. The clinical stage biopharmaceutical company, headquartered in Gaithersburg, expects to begin volunteer enrollment in the trials in the coming week, according to a statement from the company. “We believe […]

Novavax, a vaccine development company headquartered in Gaithersburg, has initiated Phase 3 for its COVID-19 vaccine candidate.  It is the fifth candidate to reach Phase 3 in the U.S., after Pfizer, Moderna, AstraZeneca and Janssen. Novavax is looking for volunteers to participate in vaccine trials, particularly those who are part of at-risk populations like Hispanics, […]

AstraZeneca, a multinational pharmaceutical company with a Gaithersburg campus, announced Monday that its COVID-19 vaccine candidate shows a 70% average efficacy rate. The vaccine candidate AZD1222 was administered in two ways. It showed 90% efficacy when it was given as a half dose and followed by a full dose at least one month later, according […]